Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Change in Account Payables: 2019-2024

Historic Change in Account Payables for Compass Therapeutics (CMPX) over the last 6 years, with Dec 2024 value amounting to -$1.8 million.

  • Compass Therapeutics' Change in Account Payables rose 315.52% to $500,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 258.62%. This contributed to the annual value of -$1.8 million for FY2024, which is 360.03% down from last year.
  • Latest data reveals that Compass Therapeutics reported Change in Account Payables of -$1.8 million as of FY2024, which was down 360.03% from $708,000 recorded in FY2023.
  • Compass Therapeutics' 5-year Change in Account Payables high stood at $2.5 million for FY2022, and its period low was -$1.8 million during FY2024.
  • Over the past 3 years, Compass Therapeutics' median Change in Account Payables value was $708,000 (recorded in 2023), while the average stood at $460,667.
  • As far as peak fluctuations go, Compass Therapeutics' Change in Account Payables skyrocketed by 1,396.39% in 2022, and later plummeted by 360.03% in 2024.
  • Yearly analysis of 5 years shows Compass Therapeutics' Change in Account Payables stood at $432,000 in 2020, then tumbled by 144.91% to -$194,000 in 2021, then surged by 1,396.39% to $2.5 million in 2022, then slumped by 71.85% to $708,000 in 2023, then crashed by 360.03% to -$1.8 million in 2024.